COPD is pathogenically associated with oxidative stress, which originates not only from cigarette smoke, but
also from hypoxia, infection, inflammation, and ageing. It is the reason that therapeutic strategies aim at attenuation of
oxidative stress, its sources, or intracellular signals and pro-inflammatory network of its downstream. This review discusses
the pathogenesis of COPD and its current therapy in viewpoint of oxidative stress and further provides the perspectives
for new treatment strategies in COPD and recent patents that could develop into novel therapeutics.
Keywords: Arachidonic acid, COPD, inflammation, neutrophil, oxidative stress, CORTICOSTEROID RESISTANCE, NEUTROPHILIC INFLAMMAION, CIGARETTE SMOKE, INFLAMM-AGEING, HYPOXIA
Rights & PermissionsPrintExport